Neuroprotection in multiple sclerosis: a therapeutic approach.

abstract：BACKGROUND:There is growing epidemiological evidence that opioids may increase the risk of unintentional injuries and it is plausible that the time of initiation is most critical in that respect. Studies on fall-related injuries remain few, limited and mostly focused on specific groups of elderly patients. OBJECTIVE:T...

journal_title：CNS drugs

authors： Söderberg KC,Laflamme L,Möller J

更新日期：2013-02-01 00:00:00

abstract：:This article reviews the conceptual progression in the pharmacological therapy of malignant astrocytoma (MA) over the past decade, and its future trends. It is a selective rather than an exhaustive inventory of literature citations. The experience of the Brain Tumour Cooperative Group (BTCG) and earlier phase III tria...

journal_title：CNS drugs

authors： Jennings MT,Iyengar S

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND:Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively impacting health-related quality of life, productivity, and daily activities. Walking impairment is consistently reported as one of the most distressing impairments by ...

journal_title：CNS drugs

authors： Hobart J,Ziemssen T,Feys P,Linnebank M,Goodman AD,Farrell R,Hupperts R,Blight AR,Englishby V,McNeill M,Chang I,Lima G,Elkins J,ENHANCE study investigators.

更新日期：2019-01-01 00:00:00

abstract：:Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of condition...

journal_title：CNS drugs

authors： McTague A,Cross JH

更新日期：2013-03-01 00:00:00

abstract：:Despite the established efficacy of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies, translating CAR T therapy to solid tumors has remained investigational. Glioblastoma, the most aggressive and lethal form of primary brain tumor, has recently been among the malignancies being trialed clinic...

journal_title：CNS drugs

authors： Salinas RD,Durgin JS,O'Rourke DM

更新日期：2020-02-01 00:00:00

abstract：OBJECTIVES:Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine. METHODS:The records of ...

journal_title：CNS drugs

authors： Mazzone L,Reale L,Mannino V,Cocuzza M,Vitiello B

更新日期：2011-06-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Patients with focal seizures recruited into adjunctive antiepileptic drug (AED) trials have become more refractory and severe over time; concurrently, placebo responses have increased. To attempt to account for heterogeneity among trials, propensity-score weighted patient-level data were used t...

journal_title：CNS drugs

authors： Swallow E,Fang A,Signorovitch J,Plumb J,Borghs S

更新日期：2017-10-01 00:00:00

abstract：:Multiple stimulant and non-stimulant medications are approved for the treatment of attention-deficit/hyperactivity disorder (ADHD), one of the most prevalent childhood neurodevelopmental disorders. Choosing among the available agents and determining the most effective ADHD medication for a given child can be a time-co...

journal_title：CNS drugs

authors： Elsayed NA,Yamamoto KM,Froehlich TE

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:A recent large database analysis raised concerns of potential acute kidney injury (AKI) risk associated with antipsychotics. However, whether individual atypical and typical antipsychotics are associated with differential AKI risks has not been investigated. OBJECTIVE:The current study compared the risks of...

journal_title：CNS drugs

authors： Jiang Y,McCombs JS,Park SH

更新日期：2017-04-01 00:00:00

abstract：:Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Varenicline was an effective aid to smoking cessation and was generally well tolerated in clinical trials, although more data are needed regarding the ...

journal_title：CNS drugs

authors： Keating GM,Lyseng-Williamson KA

更新日期：2010-09-01 00:00:00

abstract：:Naltrexone is a μ-opioid receptor antagonist that blocks the euphoric effects of heroin and prescription opioids. In order to improve treatment adherence, a once-monthly, intramuscular, extended-release formulation of naltrexone (XR-NTX) [VIVITROL(®)] has been developed, and approved in the USA and Russia for the prev...

journal_title：CNS drugs

authors： Syed YY,Keating GM

更新日期：2013-10-01 00:00:00

abstract：:Lacosamide (Vimpat(®)) is a functionalized amino acid available orally (as a syrup or tablet) and as an intravenous infusion. It is believed to exert its antiepileptic effect by selectively enhancing the slow inactivation of voltage-gated sodium channels. Lacosamide is approved in several countries worldwide as an adj...

journal_title：CNS drugs

authors： Hoy SM

更新日期：2013-12-01 00:00:00

abstract：:New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one ...

journal_title：CNS drugs

authors： Connor DF,Steingard RJ

更新日期：2004-01-01 00:00:00

abstract：:Multiple sclerosis (MS) has a profound impact on health-related quality of life (HRQoL), a comprehensive subjective measure of the patient's health status. Assessment of HRQoL informs on the potential advantages and disadvantages of disease-modifying drugs (DMDs) beyond their effects on observer-based disability and m...

journal_title：CNS drugs

authors： Jongen PJ

更新日期：2017-07-01 00:00:00

abstract：:Subacute sclerosing panencephalitis (SSPE) is a chronic progressive, usually fatal disease of uncertain pathogenesis that is associated with the presence of mutant measles virus in the CNS. The diagnosis is based on clinical criteria and an elevated titre of measles antibodies in the CSF. Electroencephalography, imagi...

journal_title：CNS drugs

authors： Anlar B

更新日期：1997-02-01 00:00:00

abstract：:NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions. ...

journal_title：CNS drugs

authors： Papadopoulos D,Mitsikostas DD

更新日期：2019-01-01 00:00:00

abstract：:The common strategy to treat a migraine attack as soon as it begins, made for classical acute antimigraine treatments such as ergotamine and analgesics, has not been transposed to the triptans. The recommendation to delay triptan intake until headache intensity is at least moderate is merely a habit generated by the p...

journal_title：CNS drugs

authors： Schoenen J

更新日期：2001-01-01 00:00:00

abstract：:Loxapine is a well-established, first-generation antipsychotic agent. Loxapine inhalation powder (Adasuve(®)) was recently approved in the USA and the EU for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. Inhaled loxapine is delivered by a hand-held, single-dose, single-use...

journal_title：CNS drugs

authors： Keating GM

更新日期：2013-06-01 00:00:00

abstract：:Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomiz...

journal_title：CNS drugs

authors： Deeks ED,Keating GM

更新日期：2010-01-01 00:00:00

abstract：:Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), oth...

journal_title：CNS drugs

authors： Haumann R,Videira JC,Kaspers GJL,van Vuurden DG,Hulleman E

更新日期：2020-11-01 00:00:00

abstract：:Topiramate is an antiepileptic drug that has a broad spectrum of antiseizure effects, which appear to be the result of several neurostabilising pharmacological mechanisms. These include blockade of ion channels, potentiation of GABA neuroinhibition and glutamate receptor antagonism at non-NMDA receptors, as well as mi...

journal_title：CNS drugs

authors： Waugh J,Goa KL

更新日期：2003-01-01 00:00:00

abstract：:Treatment of pediatric migraine remains an unmet medical need. There continues to be a paucity of pediatric randomized controlled trials for the treatment of migraine, both in the acute and preventive settings. Pediatric studies are often complicated by high placebo-response rates and much of our current practice is b...

journal_title：CNS drugs

authors： Kacperski J,Hershey AD

更新日期：2016-09-01 00:00:00

abstract：:Parkinson's disease is a disabling hypokinetic neurological movement disorder in which the aetiology is unknown in the majority of cases. Current pharmacological treatments, though effective at restoring movement, are only symptomatic and do nothing to slow disease progression. Electrophysiological, epidemiological an...

journal_title：CNS drugs

authors： Swart T,Hurley MJ

更新日期：2016-12-01 00:00:00

abstract：:In recent years, several new antiepileptic drugs (AEDs) have been licensed: felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide. These drugs have proven efficacy as add-on therapy in patients with difficult-to-treat partial epilepsy, as 20-50% of patients ...

journal_title：CNS drugs

authors： Deckers CL,Knoester PD,de Haan GJ,Keyser A,Renier WO,Hekster YA

更新日期：2003-01-01 00:00:00

abstract：:Alzheimer's disease (AD) is frequently associated with neuropsychiatric symptoms (NPS) such as agitation and aggression, especially in the moderate to severe stages of the illness. The limited efficacy and high-risk profiles of current pharmacotherapies for the management of agitation and aggression in AD have driven ...

journal_title：CNS drugs

authors： Liu CS,Chau SA,Ruthirakuhan M,Lanctôt KL,Herrmann N

更新日期：2015-08-01 00:00:00

abstract：:Aripiprazole (Abilify(®)) is an atypical antipsychotic that is widely used in the treatment of psychiatric conditions. Unlike other currently available atypical antipsychotics that primarily have varying degrees of dopamine D2 receptor antagonism, aripiprazole is a partial agonist at D2 and serotonin 5-HT1A receptors,...

journal_title：CNS drugs

authors： McKeage K

更新日期：2014-02-01 00:00:00

abstract：:A wide range of support is available to help smokers to quit and to aid attempts at harm reduction, including three first-line smoking cessation medications: nicotine replacement therapy, varenicline and bupropion. Despite the efficacy of these, there is a continual need to diversify the range of medications so that t...

journal_title：CNS drugs

authors： Beard E,Shahab L,Cummings DM,Michie S,West R

更新日期：2016-10-01 00:00:00

abstract：BACKGROUND:Refractory status epilepticus (RSE) is an emergency with high mortality requiring neurointensive care. Treatment paradigms include first-generation antiepileptic drugs (AEDs) and anesthetics. Lacosamide (LCM) is a new AED, holding promise as a potent treatment option for RSE. High-level evidence regarding sa...

journal_title：CNS drugs

authors： Sutter R,Marsch S,Rüegg S

更新日期：2013-04-01 00:00:00

abstract：:How a woman responds to sexual cues is highly dependent on a number of distinct, yet related, factors. Researchers have attempted to explain the female sexual response for decades, but no single model reigns supreme. Proper female sexual function relies on the interplay of somatic, psychosocial and neurobiological fac...

journal_title：CNS drugs

authors： Kingsberg SA,Clayton AH,Pfaus JG

更新日期：2015-11-01 00:00:00

abstract：:The anilidopiperidine opioid remifentanil has pharmacodynamic properties similar to all opioids; however, its pharmacokinetic characteristics are unique. Favourable pharmacokinetic properties, minimally altered by extremes of age or renal or hepatic dysfunction, enable easy titration and rapid dissipation of clinical ...

journal_title：CNS drugs

authors： Beers R,Camporesi E

更新日期：2004-01-01 00:00:00